As transcatheter aortic valve replacement (TAVR) expands in use as an alternative to surgical AVR (SAVR) for patients with severe symptomatic aortic valve stenosis across a wide spectrum of surgical risk, which patients are still best served by SAVR?

That question is at the center of a comprehensive State of the Art Review recently published in the European Heart Journal by an international team of expert cardiologists and cardiothoracic surgeons.